MDGLMadrigal Pharmaceuticals, Inc.
$471.93+7.3% 1Y
$471.93
$412.3552 weeks$602.83
The financials
Madrigal Pharmaceuticals, Inc. by the numbers
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $364M in Q2 2026 (quarter ended Jun 30, 2026), up 71% from the same quarter a year earlier. That came with net loss of $58M. For the full year FY2025, revenue was $958M (+432% year on year) and net income −$288M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $364M | $213M | +71% |
| Operating income | −$56M | −$47M | n/a |
| Net income | −$58M | −$42M | n/a |
| Diluted EPS | −$1.99 | −$1.50 | n/a |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $364.3M (+17%)
Reportable grew +71% year on year
Segment Latestquarter on quarteryear on year
- Reportable$364.3M$364.3Mquarter on quarter +17%year on year +71%+17%+71%